Efficacy and Safety of Canagliflozin in the Treatment of Type 2 Diabetes With Mild Cognitive Impairment

NCT07711171 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Type 2 Diabetes Mellitus
Cognitive Impairment

Interventions

DRUG: Canagliflozin group
DRUG: Sitagliptin
DRUG: Acarbose

Sponsor

Fudan University